Turing Pharma names chairman to replace Shkreli as CEO
(Reuters) - Martin Shkreli, the poster boy for prescription drug price increases who was arrested for securities fraud this week, has stepped down from his post as chief executive officer of Turing Pharmaceuticals Inc, the company said on Friday. Shkreli was replaced by Turing Chairman Ron Tilles, who said in a statement that the company was committed to continuing to make its flagship drug, Daraprim, which is used to treat an infection called toxoplasmosis in AIDS patients. Shkreli has become a lightning rod for growing outrage over soaring prescription drug prices after the company acquired Daraprim and raised its price to $750 a tablet from $13.50.
Author: Regular Articles
Tell a friend